InvestSMART

Sienna Cancer Diagnostics Limited (ASX: SDX) - Share Price

DELISTED - Current share price for SDX : $0.070

SDX General Information +

ASX Code SDX
Website N/A
Industry/Sector Biotechnology
Market Cap ($M) n/a
SDX Share Price $0.070
Day High $0.071
Day Low $0.070
Last Close $0.070
SDX Share Price Movement - ( No change )
Prices as at 16:35, 30 Jul 2020
+Security prices are delayed by at least 20 minutes and are indicative only.

Sienna Cancer Diagnostics Limited (SDX) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Sienna Cancer Diagnostics Limited (SDX) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Sienna Cancer Diagnostics Limited (SDX) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Sienna Cancer Diagnostics Limited (SDX)
ORDINARY FULLY PAID
 Health Care - Removal from Official List 29 Jul 2020 9:05AM $0.070 $0.070 fallen by 0%
Sienna Cancer Diagnostics Limited (SDX)
ORDINARY FULLY PAID
 Health Care - BD1: BARD1 COMPLETES SIENNA ACQUISITION 28 Jul 2020 6:32PM $0.070 $0.070 fallen by 0%
Sienna Cancer Diagnostics Limited (SDX)
ORDINARY FULLY PAID
 Health Care - Implementation of Scheme of Arrangement 28 Jul 2020 5:40PM $0.070 $0.070 fallen by 0%
Sienna Cancer Diagnostics Limited (SDX)
ORDINARY FULLY PAID
 Health Care - Suspension from Official Quotation 20 Jul 2020 7:03PM $0.070 $0.070 fallen by 0%
Sienna Cancer Diagnostics Limited (SDX)
ORDINARY FULLY PAID
 Health Care - Lodgement of Court Order Scheme becomes effective 20 Jul 2020 1:16PM $0.071 $0.070 fallen by 1.41%
Sienna Cancer Diagnostics Limited (SDX)
ORDINARY FULLY PAID
 Health Care - Court Approves Scheme of Arrangement 20 Jul 2020 10:49AM $0.070 $0.070 fallen by 0%

SDX Directors

Name Position Start Date
Mr Tony Di Pietro Chief Financial Officer, Company Secretary, Non-Executive Director 6 Feb 2020
Dr Geoffrey James Cumming Non-Executive Chairman, Non-Executive Director 27 Jan 2006
Ms Helen E Fisher Non-Executive Director 28 Mar 2018
Mr Carl Stubbings Non-Executive Director, Chief Executive Officer 31 Dec 2011

Sienna Cancer Diagnostics Limited (SDX) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
28 Aug 2018 CHIPLIN, John Issued Indirect Shares 40,000 $0.060 $2,400.000
28 Aug 2018 STUBBINGS, Carl Issued Indirect Shares 64,659 $0.041 $2,679.540
28 Aug 2018 CUMMING, Geoffrey Issued Indirect Shares 282,954 $0.060 $16,977.240

See all changes in directors' interest & trades for Sienna Cancer Diagnostics Limited (SDX) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

SDX Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in -- (SDX). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
24,566,667 (8.50%) Merchant Funds Management Pty Ltd
20,450,000 (7.07%) David Williams and related entities
18,852,970 (6.52%) David Neate

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.